Fortune Brands Innovations — May 6, 2025 release
Fiscal 2025 first-quarter results · 8-K Item 2.02 · Exhibit 99.1 · 0000950170-25-064485
Showing in the filing
Net debt to EBITDA before charges / gains
“between 2.0x and 2.5x”
Period
FY2025
Measure
Company-defined measure
Source
Prose
All guidance in this release · 1
Net debt to EBITDA before charges / gains for FY2025
“between 2.0x and 2.5x”
Exhibit 99.1 · the passage around this item
… earlier in the release
In accordance with its opportunistic, returns-based share repurchase program, the Company repurchased $175 million of shares in the quarter, and as of May 6, 2025, has repurchased $225 million of shares year to date. The Company expects to finish the year with net debt to EBITDA before charges / gains between 2.0x and 2.5x. As of the end of the first quarter 2025:
Net debt
$2.6 billion
Net debt to EBITDA before charges / gains
2.8x
Cash
$340 million
Amount available under revolving credit facility
$970 million
2025 Full-Year Guidance Due to uncertainty around consumer demand and volumes, the Company is not providing detailed 2025 full-year guidance. However, the Company is providing the framework for EPS before charges / gains scenarios based on different volume assumptions that will be outlined during the first quarter earnings call. Fortune Brands’ teams are working on mitigating the expected impact of tariffs quickly and strategically through sourcing moves, cost out opportunities and strategic pricing. The Company remains confident in its long-term strategy of focusing on categories driven by brands and innovation, with an emphasis on attractive areas of its core and acceleration in its digital strategy. For forward-looking non-GAAP measures (as used in this press release, net debt to EBITDA before charges / gains), the Company is unable to provide a reconciliation to the most comparable GAAP financial measure because the information needed to reco
later in the release …
the item shown at left
other guidance in this release
Text is the filed exhibit, verbatim.